The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response has awarded a $9,271,193.00 Firm Fixed Price contract to Vaxart Biosciences Inc. to conduct clinical trial planning activities for a Phase 2b clinical trial comparing Vaxart's XBB vaccine candidate to an mRNA comparator. The trial will evaluate efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and adverse events. This definitive contract has an ultimate completion date of October 31, 2024 and was awarded on January 12, 2024. The contract does not have a set-aside designation.
Generated 7/13/24, 9:02 AM